Anti-ageing pipeline starts to mature

Ongoing and upcoming clinical trials of metformin, mTOR inhibitors and senescent cell-killing drugs could prove that ageing and ageing-related diseases are viable drug discovery indications.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mullard, A. Anti-ageing pipeline starts to mature. Nat Rev Drug Discov 17, 609–612 (2018).

Download citation

Further reading


Quick links

Sign up for the Nature Briefing newsletter for a daily update on COVID-19 science.
Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing